Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 3,478	$ 6,750	$ 6,071	$ 12,039
General and administrative	4,008	2,803	6,881	5,555
Acquired in-process research and development			164,617
Total operating expenses	7,486	9,553	177,569	17,594
Loss from operations	(7,486)	(9,553)	(177,569)	(17,594)
Other income (expense):
Interest and investment income	40	60	53	227
Other expense, net	(20)	(15)	(34)	(93)
Total other income, net	20	45	19	134
Net loss	(7,466)	(9,508)	(177,550)	(17,460)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs	(24,437)		(24,437)
Net loss attributable to common shareholders	$ (31,903)	$ (9,508)	$ (201,987)	$ (17,460)
Net loss per share - basic and diluted	$ (0.89)	$ (0.53)	$ (6.93)	$ (1.03)
Weighted-average common shares outstanding used in net loss per share - basic and diluted	35,880,580	17,967,495	29,167,672	16,933,079